Jihua has served on the board of directors of since January 2017. As a member of the first generation of pioneers in establishing private biotechnology companies in China, Jihua founded Guangzhou Wondfo Biotech Co., Ltd, in 1992, and served as the CEO until June 2016. After leading the company to IPO in 2015, Jihua has been appointed Chairman of the Board since July 2016. Since 2009, Jihua has bee

Alex joined binx health in 2018 as a co-founder of the digital testing platform which provides scalable, compliant, and convenient solutions to managing population health concerns. His expertise has been critical in setting the company’s digital product vision and strategy, and for guiding the product engineering activities. Alex is a highly experienced healthcare and laboratory diagnostics produc

Jeff Grosklags is the Chief Financial Officer (CFO) of Optum Rx. Jeff provides the financial strategy and leadership needed to succeed in improving the quality and affordability of health care. Prior to becoming CFO of Optum Rx, Jeff held a number of senior leadership positions within UnitedHealth Group, including CFO of Optum Health Care Solutions, Optum Health Care Delivery and COO and CFO of

Jack is an experienced Chief Financial Officer with a long track record of success with Fortune 500 and Private Equity backed companies. Following his start in public accounting as senior manager at PricewaterhouseCoopers, Jack has held numerous leadership positions at both public and private companies including Thermofisher Scientific, Biogen, Lantheus Medical Imaging, and PGDx. At every step alo

Joachim (JR) Rothe, PhD, joined LSP in 2002 and is a Managing Partner of the firm. Prior to joining LSP, Joachim was the Managing Director of MPM Capital Germany, a US healthcare investment firm, where he rose to head up their European investment franchise. Previously, he worked at McKinsey & Company in Germany and at Roche in Switzerland. He serves or has served on the boards of 4-Antibody (CH, n

As CTO, Anna plays a core leadership role at the binx health UK site, and is responsible for over-seeing and coordinating all technical product development activities. She leads in the expansion of the product menu, evolving the companys’ technology vision and strategy, as well as exploring novel applications of our core technology. Anna joined the company in 2007 and has extensive experience and

Dr. Moonly is a former investment banker at Merrill Lynch where he was an analyst on the largest Biotech Merger at that time – Amgen’s purchase of Immunex. Additionally, he completed a follow on offering for biotech, and analyzed multiple M&A deals in the medical technology space.

Scott was also a strategy consultant with L.E.K. Consulting where he developed the Oncology strategy for a large Biot

Dr. Münchbach has been a Managing Partner and Investment Advisor Private Equity at BB Biotech Ventures and Bellevue Asset Management since 2004. He has been an active venture capitalist since the late 90’s investing in life science companies across all stages and types. Prior to joining Bellevue Group, he was Investment Manager at BioMed, HBM, and NMT. Dr. Münchbach’s past and current board assign

Abby joined binx health in 2022 with a focus on making binx everywhere available and billable to commercial insurance companies. As our Vice President of Business Development & Market Access, Abby supports our business development efforts for both product lines as well as manages all enterprise digital sales verticals including payers, health systems, retail pharmacies, employers, and universiti

Mr. Hwang currently is Head of Corporate Development and Strategic Planning at Recipharm AB, a top 5 global CDMO. He is responsible for managing strategic investments, partnerships and mergers and acquisitions (M&A) globally. Mr. Hwang has more than 19 years of experience in corporate development, venture investment, corporate financing, and M&A and has worked on over $5 billion worth of transact

Jack Kaminski is Chief Product Supply Officer for binx. He has worked in operations leadership roles over the past 35 years for the Gillette Company, Keurig Green Mountain and most recently Willow Innovation. Jack has extensive consumer product, healthcare, manufacturing & supply chain, hypergrowth and international business experience.

Jack joined Gillette’s Oral-B Laboratories division in 1987

Mr. Goldman is Co-Founder and Managing Partner at Hildred Capital Management. Mr. Goldman previously served as Managing Director and Chief Investment Officer of Hildred Capital Partners, where he was responsible for overseeing Hildred’s capital allocation and day-to-day investing activities. Since joining Hildred in 2015, Mr. Goldman, in concert with Mr. Solomon, has overseen the management of the

Todd’s industry background includes over 28 years’ experience and demonstrated performance excellence in the in-vitro diagnostics and biotechnology industries. He has extensive expertise in executive leadership, general commercial management, business development, global marketing, strategic planning, executive sales, marketing and customer service management across multiple diagnostic channels in

Stanley founded EXACT Sciences and served as its CEO and Chairman until 2006. Since commercial introduction of the company’s Cologuard test for non-invasive, early detection of colorectal cancer, EXACT has been the most rapidly growing company in the history of the diagnostics industry. Prior to EXACT Sciences, Stanley was founder and CEO of Cytyc Corp prior to its acquisition by Hologic for $6.2

Naomi Kelman has served as a director since July 2021. Ms. Kelman is the former president and chief executive officer of Willow Innovations Inc, a revolutionary new women’s health company, having served in that role from 2014 to 2019. From 2011 to 2012, Ms. Kelman served as the global division head of Novartis OTC at Novartis AG. Prior to that, Ms. Kelman served in a number of executive roles duri

Pia joined binx in March of 2022 as our Senior Vice President of Human Resources. She is a strategic HR leader with over 20 years of extensive experience in all Human Resources functions. Pia has held leadership roles at multiple large and small life science companies, both public and private, including Wyeth, Pfizer, Lantheus Medical Imaging and Ora, Inc. Her strength is partnering with executive

Jeff has served as CEO of multiple life science companies in emerging healthcare markets with both public and private venture-backed companies. Prior to binx health, Jeff served as President, Chief Executive Officer, and Director of Good Start Genetics, a commercial stage provider of advanced genetic testing in reproductive health, with operations in all fifty states in the US. Under Jeff’s leader

Jeff has served as CEO of multiple life science companies in emerging healthcare markets with both public and private venture-backed companies. Prior to binx health, Jeff served as President, Chief Executive Officer, and Director of Good Start Genetics, a commercial stage provider of advanced genetic testing in reproductive health, with operations in all fifty states in the US. Under Jeff’s leader